TY - JOUR
T1 - Multidrug chemotherapy using bleomycin, methotrexate, and cisplatin combined with radical radiotherapy in advanced head and neck cancer
AU - Zidan, J.
AU - Kuten, A.
AU - Cohen, Y.
AU - Robinson, E.
PY - 1987/1/1
Y1 - 1987/1/1
N2 - Thirty‐one patients with Stage III‐IV head and neck squamous cell cancer were treated by three courses of combination chemotherapy using bleomycin, methotrexate, and cisplatin followed by a radical course of radiation and in two cases by surgery. Of 29 evaluable patients, 4 (14%) achieved complete remission (CR) with chemotherapy and 13 (45%) had a partial response (PR). With the addition of radiotherapy and surgery, the CR rate increased to 72%. At 30 months the actuarial survival of all evaluable patients was 61% and of complete responders, 76%. Patients with nasopharyngeal cancer had an actuarial survival of 80% at 30 months, whereas patients with squamous malignancies at other sites in the head and neck region had an actuarial survival of only 37%. Side effects were tolerable. It is concluded that complete responders to combination chemotherapy and radiotherapy have a survival benefit at 30 months. The combined approach is most effective in nasopharyngeal cancer. Cancer 59:24–26, 1987.
AB - Thirty‐one patients with Stage III‐IV head and neck squamous cell cancer were treated by three courses of combination chemotherapy using bleomycin, methotrexate, and cisplatin followed by a radical course of radiation and in two cases by surgery. Of 29 evaluable patients, 4 (14%) achieved complete remission (CR) with chemotherapy and 13 (45%) had a partial response (PR). With the addition of radiotherapy and surgery, the CR rate increased to 72%. At 30 months the actuarial survival of all evaluable patients was 61% and of complete responders, 76%. Patients with nasopharyngeal cancer had an actuarial survival of 80% at 30 months, whereas patients with squamous malignancies at other sites in the head and neck region had an actuarial survival of only 37%. Side effects were tolerable. It is concluded that complete responders to combination chemotherapy and radiotherapy have a survival benefit at 30 months. The combined approach is most effective in nasopharyngeal cancer. Cancer 59:24–26, 1987.
UR - http://www.scopus.com/inward/record.url?scp=0023138776&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19870101)59:1<24::AID-CNCR2820590109>3.0.CO;2-M
DO - 10.1002/1097-0142(19870101)59:1<24::AID-CNCR2820590109>3.0.CO;2-M
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 2431756
AN - SCOPUS:0023138776
SN - 0008-543X
VL - 59
SP - 24
EP - 26
JO - Cancer
JF - Cancer
IS - 1
ER -